<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Chapter 9: Drugs used in chronic conditions 2 - Pharmacology Study Guide</title>


    
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<link rel="stylesheet" href="../styles/main.css">

  <div class="reading-progress-container">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="page-wrapper">
    <div class="container">
        <nav class="breadcrumb" aria-label="Breadcrumb">
            <ol class="breadcrumb-list">
                <li class="breadcrumb-item"><a href="../index.html">Home</a></li>
                <li class="breadcrumb-item active" aria-current="page">Chapter 9</li>
            </ol>
        </nav>

        <main class="document-article" id="main-content">
            <header class="document-header">
                <div class="header-badge">Chronic Conditions</div>
                <h1 class="document-title">Drugs used in chronic conditions 2</h1>
                <div class="title-meta">
                    <span class="meta-item">
                        <span class="meta-icon">üß¨</span>
                        <span>Diabetes Mellitus</span>
                    </span>
                    <span class="meta-item">
                        <span class="meta-icon">üíä</span>
                        <span>Insulin & Oral Agents</span>
                    </span>
                </div>
            </header>

            <div class="content-wrapper">
                <!-- Learning Objectives -->
                <section class="content-section">
                    <div class="callout callout--note">
                        <div class="callout-header">
                            <span class="callout-icon">üéØ</span>
                            <h3 class="callout-title">Learning Objectives</h3>
                        </div>
                        <div class="callout-content">
                            <p>After studying this chapter you should be able to:</p>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Describe the basic pathology involved in Diabetes Mellitus.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Discuss the differences in onset and progression of Type I and Type II diabetes.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Explain the mode of action of medicines used in treating these conditions.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Demonstrate an understanding of the unwanted effects of medicines used in treating these conditions.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Discuss the differences in medication use between Type I and Type II diabetes.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Demonstrate an understanding of the links between the pharmacology of therapies used in treating Diabetes and the care given by the health practitioner.</span>
                                </li>
                            </ul>
                        </div>
                    </div>
                </section>

                <!-- Introduction -->
                <section class="content-section">
                    <h2 class="section-title">Introduction</h2>
                    <p>It is a fact that in today's society there are an increasing number of patients with the condition diabetes mellitus. In this chapter you will learn about the two types of diabetes and their similarities and differences. Having this knowledge will make the range of drug choices in diabetes easier to understand.</p>
                </section>

                <!-- Diabetes Overview -->
                <section class="content-section">
                    <h2 class="section-title">Diabetes</h2>
                    <p>Diabetes mellitus is a chronic disease of metabolism caused by either an insufficient production of insulin in the body or an insufficient effect of insulin in the peripheral tissues. The main problems stem from a wide fluctuation in the range of blood glucose levels which leads to a number of short- and long-term difficulties for the individual. There are two main forms of diabetes: type I and type II.</p>

                    <div class="callout callout--tip">
                        <div class="callout-header">
                            <span class="callout-icon">üí°</span>
                            <span class="callout-title">Clinical Tip</span>
                        </div>
                        <div class="callout-content">
                            <p>Sometimes professionals will refer to type I diabetes as 'juvenile' because it usually starts before the age of 40 and is most common in the teenage years.</p>
                        </div>
                    </div>

                    <p>In <strong>type I diabetes</strong> the body produces little or no insulin in cells contained in the pancreas and known as the 'Islets of Langerhans' or the beta cells. The pancreas is a specialized gland that lies just behind the stomach. Its functions range from regulating the amount of sugar (glucose) you have in your blood to producing enzymes that help break down and digest proteins, carbohydrates and fats. It is thought that the beta cells in the pancreas are destroyed by the body's own immune response: hence diabetes is an autoimmune disease. Someone with type I diabetes will be required to take insulin for the rest of their lives.</p>

                    <div class="callout callout--tip">
                        <div class="callout-header">
                            <span class="callout-icon">üí°</span>
                            <span class="callout-title">Clinical Tip</span>
                        </div>
                        <div class="callout-content">
                            <p>Sometimes you will hear people refer to type II diabetes as 'maturity onset' as it occurs in people over the age of 40.</p>
                        </div>
                    </div>

                    <p>In <strong>type II diabetes</strong> the beta cells may produce small amounts of insulin but not enough to control the levels of glucose in the plasma. In addition, the cells of the body, and particularly in the periphery, cannot utilize insulin properly. This means that glucose is not allowed to enter peripheral cells, so increasing the glucose levels in the plasma. This type of diabetes is linked to the problem of obesity.</p>

                    <p>It is estimated that approximately 2 million people in the UK are currently being treated for type II diabetes. However, researchers suggest that there are as many people who are under-diagnosed. The risk of this type of diabetes is also higher if it runs in the family or if the patient is overweight. From this perspective, it is clear that prevention of obesity will also lead to prevention of type II diabetes.</p>

                    <!-- Box 9.1: Comparison Table -->
                    <div class="content-card">
                        <h3 class="card-title">Box 9.1 The two types of diabetes</h3>
                        <div class="table-wrapper">
                            <div class="table-container">
                                <table class="content-table">
                                    <thead>
                                        <tr>
                                            <th>Feature</th>
                                            <th>Type I</th>
                                            <th>Type II</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Other names</strong></td>
                                            <td>Juvenile onset diabetes<br>Insulin-dependent diabetes (IDDM)</td>
                                            <td>Maturity onset diabetes<br>Non-insulin dependent diabetes (NIDDM)</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Description</strong></td>
                                            <td>Little or no insulin produced by the pancreas; insulin is required to sustain life.</td>
                                            <td>Pancreas doesn't make enough insulin, or body doesn't use insulin correctly.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Usual age of onset</strong></td>
                                            <td>Less than 20 years</td>
                                            <td>40-60 years</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Control by oral hypoglycaemics</strong></td>
                                            <td>No</td>
                                            <td>Yes; certainly in the first instance</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Control by insulin</strong></td>
                                            <td>Yes</td>
                                            <td>Not initially; may be required as disease progresses</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Symptoms</strong></td>
                                            <td>Rapid onset: frequent micturition, extreme hunger/thirst, weight loss, weakness, nausea.</td>
                                            <td>Slow onset: increased thirst/micturition, fatigue, slow wound healing, recurrent infections.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Complications</strong></td>
                                            <td>DKA, hypoglycaemia, nephropathy, retinopathy, macrovascular disease, neuropathy.</td>
                                            <td>Hyperglycaemic coma, hypoglycaemia, nephropathy, retinopathy, macrovascular disease, neuropathy.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </div>

                    <p>Without treatment, the main symptoms of diabetes can be divided into two major areas: acute symptoms and chronic complications. There are a number of symptoms that could be referred to as 'classic'. These are excessive thirst (polydypsia), producing lots of urine necessitating many trips to the toilet (polyuria), blurring of vision, tiredness and weight loss due to muscle wasting.</p>

                    <div class="callout callout--tip">
                        <div class="callout-header">
                            <span class="callout-icon">üí°</span>
                            <span class="callout-title">Clinical Tip</span>
                        </div>
                        <div class="callout-content">
                            <p><strong>Macrovascular disease</strong> refers to damage to the larger blood vessels and results in coronary heart disease or peripheral vascular disease. <strong>Microvascular disease</strong> refers to damage to smaller vessels, resulting in eye problems (retinopathy) and kidney damage (nephropathy). Damage to the outside of the nerves is referred to as <strong>neuropathy</strong>.</p>
                        </div>
                    </div>

                    <h3>Diabetic ketoacidosis (DKA)</h3>
                    <p>Diabetic ketoacidosis is a condition that comes as a complication of diabetes. A patient with DKA will have high blood glucose levels (hyperglycaemia), high levels of ketone bodies in their plasma (ketosis), and because these ketone bodies are acidic the patients' blood becomes more acidic (metabolic acidosis). DKA occurs mostly in type 1 diabetes mellitus (DM).</p>
                    
                    <p>If left unchecked the condition can progress to cerebral oedema, coma, and death. Insulin deficiency can be described as absolute (e.g. missed dose) or relative (e.g. increased demand due to infection). Stressors that can cause this relative imbalance include acute infection such as pneumonia or myocardial infarction. Certain drugs are also implicated in causing DKA including corticosteroids, thiazide diuretics and sympathomimetics.</p>

                    <h3>Treatment of DKA</h3>
                    <p>The most urgent goals are:</p>
                    <ul class="enhanced-list">
                        <li class="list-item">
                            <span class="list-marker"></span>
                            <span class="list-content">Rehydration using intravenous fluids</span>
                        </li>
                        <li class="list-item">
                            <span class="list-marker"></span>
                            <span class="list-content">Correction of hyperglycaemia and acidosis</span>
                        </li>
                        <li class="list-item">
                            <span class="list-marker"></span>
                            <span class="list-content">Preventing hypokalemia (low level of potassium)</span>
                        </li>
                    </ul>
                    
                    <p>Intravenous fluids are needed immediately as intravascular volume should be restored to raise blood pressure and ensure kidney perfusion. Once initial fluids are given, the remaining deficits are corrected more slowly over 24-36 hours.</p>
                    
                    <p>Hyperglycaemia needs correcting by giving the patient regular insulin (e.g., Humulin, Novolin). Initially the patient may require 0.1 unit/kg as an IV bolus, followed by a continuous IV infusion. As the patient improves, they will be switched to subcutaneous insulin.</p>
                </section>

                <!-- Medicine Management -->
                <section class="content-section">
                    <h2 class="section-title">Medicine management of diabetes</h2>
                    <p>The overall aim of treatment is to maintain blood glucose levels within the normal range (normoglycaemia). This relieves acute symptoms and minimizes chronic complications. Lifestyle changes like exercise and smoking cessation are advisable. However, the most important key is diet, used alone or combined with insulin or oral hypoglycaemic agents.</p>

                    <h3>Insulin</h3>
                    <p>Insulin is released in the body in response to raised blood glucose. It is the key that allows glucose to enter cells. It also promotes conversion of glucose to glycogen (storage) and limits fat breakdown (lypolisis).</p>

                    <div class="callout callout--warning">
                        <div class="callout-header">
                            <span class="callout-icon">‚ö†Ô∏è</span>
                            <span class="callout-title">Administration Note</span>
                        </div>
                        <div class="callout-content">
                            <p>Insulin is destroyed in the GI system, which is why you never see it given by mouth as a tablet. It is usually given by subcutaneous (SC) injection.</p>
                        </div>
                    </div>

                    <p>At one time insulin was extracted from cattle or pigs, but today it is almost entirely human, produced via recombinant DNA technology. Once absorbed, insulin has a short half-life of approximately 10 minutes, so long-acting forms are required for control.</p>

                    <div class="callout callout--tip">
                        <div class="callout-header">
                            <span class="callout-icon">üí°</span>
                            <span class="callout-title">Clinical Tip</span>
                        </div>
                        <div class="callout-content">
                            <p>Insulin can be auto-injected by means of a device called a 'pen', or via a small insulin pump. Newer devices include jet systems that force a small stream of insulin through the skin without a needle.</p>
                        </div>
                    </div>

                    <h4>Types of Insulin</h4>
                    
                    <div class="content-card">
                        <h4 class="card-title">Short-acting insulins</h4>
                        <p>Soluble insulin produces a quick and short-lived effect. Examples include <strong>Actrapid</strong>. <strong>Insulin lispro</strong> is a special form that works even more rapidly. These are the only types suitable for IV injection.</p>
                        <p><em>Use:</em> Usually injected 15 to 30 minutes before a meal to control post-prandial glucose. Used in 'sliding scales' for DKA.</p>
                    </div>

                    <div class="content-card">
                        <h4 class="card-title">Intermediate insulins</h4>
                        <p>Longer-acting preparations made by mixing insulin with a substance that slows its use (e.g., <strong>isophane insulin</strong>).
                        <p><em>Use:</em> Starts working ~1.5 hours after administration, peaks 4-8 hours, lasts up to 24 hours.</p>
                        <div class="callout callout--note">
                            <div class="callout-content">
                                <p>Isophane insulin is cloudy. Gently roll the vial 10 times to mix before administration.</p>
                            </div>
                        </div>
                    </div>

                    <div class="content-card">
                        <h4 class="card-title">Long-acting insulins</h4>
                        <p>Includes Lente and Ultralente. <strong>Insulin glargine</strong> is a modified insulin designed to provide a constant insulin supply (mimicking basal rate), often taken once daily to maintain normoglycaemia over 24 hours.</p>
                    </div>

                    <div class="content-card">
                        <h4 class="card-title">Premixed insulins</h4>
                        <p><strong>Mixtard</strong> contains a mixture of soluble and isophane insulin (biphasic). It provides rapid initial lowering followed by a prolonged effect.</p>
                    </div>

                    <!-- Box 9.2 -->
                    <div class="callout callout--note">
                        <div class="callout-header">
                            <span class="callout-icon">üìä</span>
                            <span class="callout-title">Box 9.2: Insulin Pharmacokinetics</span>
                        </div>
                        <div class="callout-content">
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Rapid acting analogue (clear):</strong> Onset 10-15m / Peak 60-90m / Duration 4-5h</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Fast acting (clear):</strong> Onset 0.5-1h / Peak 2-4h / Duration 5-8h</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Intermediate acting (cloudy):</strong> Onset 1-3h / Peak 5-8h / Duration up to 18h</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Long acting (cloudy):</strong> Onset 3-4h / Peak 8-15h / Duration 22-26h</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Extended long acting analogue:</strong> Onset 90m / Duration 24h</span></li>
                            </ul>
                        </div>
                    </div>

                    <h3>Side-effects of Insulin</h3>
                    <p>The main problem is <strong>hypoglycaemia</strong> (blood sugar lowered too much), which can cause brain damage. Patients may become dizzy, faint, sweat, and appear drunk.</p>
                    <p><strong>Treatment:</strong> Give sugar (sweet drinks, glucose tablets). If unconscious, IV glucose or intramuscular glucagon is required.</p>

                    <h3>Insulin Pumps</h3>
                    <p>An insulin pump is portable and delivers insulin through a cannula under the skin. It uses fast-acting insulin to deliver:</p>
                    <ul class="enhanced-list">
                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Basal rate:</strong> Constant background insulin (replaces long-acting).</span></li>
                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Bolus dose:</strong> Extra boosts programmed for meals/snacks.</span></li>
                    </ul>
                </section>

                <!-- Oral Hypoglycaemic Agents -->
                <section class="content-section">
                    <h2 class="section-title">Oral hypoglycaemic agents</h2>
                    <p>These drugs are usually given for type II diabetes when diet alone is insufficient.</p>

                    <div class="content-card">
                        <h3 class="card-title">Metformin (Biguanide)</h3>
                        <p><strong>Action:</strong> Reduces liver glucose production, increases muscle sensitivity to insulin, delays GI glucose absorption.</p>
                        <p><strong>Usage:</strong> First-line treatment for Type II. Usually 500mg TDS with food.</p>
                        <p><strong>Side-effects:</strong> Anorexia, diarrhoea, nausea. Risk of lactic acidosis (rare but fatal).</p>
                    </div>

                    <div class="content-card">
                        <h3 class="card-title">Sulfonylureas</h3>
                        <p><strong>Action:</strong> Stimulate beta cells to secrete insulin. Examples: Tolbutamide, Glipizide.</p>
                        <p><strong>Side-effects:</strong> Hypoglycaemia is a major risk. Patients must be alerted to report shakiness, sweating, or dizziness.</p>
                    </div>

                    <div class="content-card">
                        <h3 class="card-title">Meglitinides</h3>
                        <p><strong>Example:</strong> Nateglinide. Enhances insulin secretion but with a short duration, reducing hypoglycaemia risk. Taken just before meals.</p>
                    </div>

                    <div class="content-card">
                        <h3 class="card-title">Thiazolidinediones (Glitazones)</h3>
                        <p><strong>Example:</strong> Pioglitazone. Reduces breakdown of stored glucose and increases muscle uptake. Doesn't cause hypoglycaemia alone.</p>
                        <p><strong>Side-effects:</strong> Weight gain, ankle swelling. May worsen heart failure. Takes weeks for full effect.</p>
                    </div>

                    <div class="content-card">
                        <h3 class="card-title">Alpha-glucosidase inhibitors</h3>
                        <p><strong>Example:</strong> Acarbose. Slows breakdown of food releasing glucose. Taken with first bite of meal.</p>
                        <p><strong>Side-effects:</strong> Flatulence, diarrhoea, bloating.</p>
                    </div>
                </section>

                <div class="document-nav">
                    <div class="nav-container">
                        <a href="topic-08-chronic-1.html" class="nav-button">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Previous: Respiratory Conditions</span>
                        </a>
                        <div class="document-progress">
                            <div class="progress-label">Chapter 9 of 13</div>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 69%;"></div>
                            </div>
                        </div>
                        <a href="topic-10-chronic-3.html" class="nav-button">
                            <span class="nav-text">Next: Hypertension & Epilepsy</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                </div>

            </div>
        </main>
    </div>
</div>

<script src="../js/theme.js"></script>
<script src="../js/progress.js"></script>
